Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients

Comparative Hepatology

Volumn 4, Issue , 2005, Pages

  Ouzan, Denis ^a   Khiri, Hacène ^b   Pénaranda, Guillaume ^c   Joly, Hélène ^a   Halfon, Philippe ^b  

^a INSTITUT ARNAULT TZANCK   (France)

^b Laboratoire Alphabio   (France)

^c CDLPharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ERADICATION THERAPY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; MALE; POLYMERASE CHAIN REACTION; PREDICTION; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

EID: 30044434843     PISSN: 14765926     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-4-9     Document Type: Article

References (28)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
2. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001, 120(6):1438-1447.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140(5):346-355.
5. Halfon P, Khiri H, Tran A, Penaranda G, Courcambeck J, Joly H, Ouzan D: Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response. Eur J Gastroenterol Hepatol 2003, 15(10):1067-1071.
6. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37(6):1351-1358.
7. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37(6):1343-1350.
8. Sarrazin C: Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. J Clin Virol 2002, 25 Suppl 3: S23-29.
9. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM: Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004, 39(6):1709-1720.
10. Bekkering FC, Brouwer JT, Hansen BE, Schalm SW: Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. J Hepatol 2001, 34(3):435-440.
11. Halfon P, Neumann AU, Bourliere M, Rieu A, Chadapaud S, Khiri H, Ouzan D, Cacoub P: Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat 2003, 10(5):351-353.
12. Fukutomi T, Nakamuta M, Fukutomi M, Iwao M, Watanabe H, Hiroshige K, Tanabe Y, Nawata H: Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001, 34(1):100-107.
13. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS: Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001, 33(2):419-423.
14. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M et al: Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005, 75(1):27-34.
15. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G: Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther 2004, 9(4):491-497.
16. Karino Y, Toyota J, Sugawara M, Miyazaki K, Kuwata Y, Yamazaki K, Sato T, Ohmura T, Matsushima T: Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003, 18(4):404-410.
17. Zeuzem S, Herrmann E: Dynamics of hepatitis C virus infection. Ann Hepatol 2002, 1(2):56-63.
18. Civeira MP, Prieto J: Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999, 31 Suppl 1:237-243.
19. Enomoto M, Nishiguchi S, Kohmoto M, Tamori A, Habu D, Takeda T, Seki S, Shiomi S: Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 2004, 11(5):448-454.
20. Rossini A, Artini M, Levrero M, Almerighi C, Massari M, Biasi L, Radaeli E, Cariani E: Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. Dig Dis Sci 2001, 46(11):2389-2395.
21. Russo MW, Fried MW: Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep 2004, 6(1):17-21.
22. Fried MW: Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev Gastroenterol Disord 2004, 4 Suppl 1:S8-S13.
23. Ferenci P: Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004, 53(1):15-18.
24. Kakumu S, Matsushima T, Sato S, Kobayashi K, Kiyosawa K, Hayashi N, Tsuji T, Sata M, Origasa H, Iino S: Serum HCV RNA levels during early phase of recombinant interferon alfa-2a (Roferon A) therapy for chronic hepatitis C and efficacy of short-term therapy with earlier loss of viremia. Hepatol Res 2002, 22(2):152-160.
25. Blendis L, Oren R, Halpern Z: Interferon treatment of HCV: do we need a virological response? Gastroenterology 2002, 122(1):237-238.
26. Halfon P, Khiri H, Gerolami V, Bourliere M, Feryn JM, Reynier P, Gauthier A, Cartouzou G: Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol 1996, 25(3):307-311.
27. Trimoulet P, Halfon P, Pohier E, Khiri H, Chene G, Fleury H: Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002, 40(6):2031-2036.
28. Halfon P, Trimoulet P, Bourliere M, Khiri H, de Ledinghen V, Couzigou P, Feryn JM, Alcaraz P, Renou C, Heury HJ et al: Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J Clin Microbiol 2001, 39(5):1771-1773.